Xeris says XP-8121 Phase 3 on track for late-2028 topline

Xeris Biopharma hosted an XP-8121 program overview, saying Phase 3 Cornerstone is on track to initiate by year-end, with topline results expected in late 2028 and potential U.S. approval and launch in 2030.